Neuronerd here. While the credentials of the people involved with this company are top-notch, I am going to have to rain on the parade here to remind people that AD treatment research is littered with examples of experimental therapies that were supposed to be The Big One and turned out to be duds when they were rolled out into larger n, well controlles trials of efficacy.

This feels to me like another one of those "too good to be true" claims. The company is privately held, but the obvious inference here is that this report is going to result in investors throwing money at them, or one of the big device companies like Medtronic attempting a buyout. This will all happen long before that next trial is completed...in two or three years.